Group 1 - Company Huazhu Sanjiu announced an investment of up to RMB 10 billion in bank wealth management products to utilize idle funds effectively, with a rolling investment period until October 9, 2026 [1] - As of June 30, 2025, Huazhu Sanjiu reported cash and trading financial assets totaling RMB 9.672 billion, alongside long-term equity investments of RMB 1.699 billion and other non-current financial assets of RMB 495 million [1][2] - The company has distributed a total cash dividend of RMB 4.166 billion over the past three years, with a proposed cash dividend of approximately RMB 751 million for the mid-2025 period [2] Group 2 - The growth in revenue is primarily driven by the prescription drug business, which saw a 100.18% increase in revenue to RMB 4.838 billion following the acquisition of Tianshili [3] - The CHC health consumer products segment, which contributes about 60% of the company's revenue, reported a revenue of RMB 8 billion in the first half of 2025, a decline of 18% year-on-year [3] - Huazhu Sanjiu's stock price closed at RMB 28.92 on September 17, 2023, with a total market capitalization of RMB 48.13 billion [5]